Major Depression



Deep Brain Stimulation of the Bilateral Habeluna for Treatment- Resistant Major Depression


Condition:   Treatment Resistant Major Depression Disorder
Interventions:   Procedure: Surgical Intervention;   Device: Shame DBS device followed by active DBS;   Device: Active DBS device followde by shame DBS
Sponsor:   Ruijin Hospital
Recruiting


Fish Oil as Adjunct Treatment for Major Depressive Disorder


Condition:   Major Depressive Disorder
Interventions:   Dietary Supplement: fish oil capsule;   Dietary Supplement: soybean oil capsule
Sponsors:   Second Xiangya Hospital of Central South University;   Xiangya Hospital of Central South University
Recruiting


Allogeneic HUman Mesenchymal Stem Cell InfusioN Versus Placebo in Subjects With Alcohol Use Disorder and Major DepreSsion.


Conditions:   Major Depression;   Alcohol Use Disorder
Interventions:   Drug: allogeneic human mesenchymal stem cells (allo-hMSCs);   Drug: Placebo
Sponsors:   Joshua M Hare;   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting


Remotely Programmed Deep Brain Stimulation of the Bilateral Habeluna for Treatment- Resistant Major Depression: An Open Label Pilot Trial


Condition:   Treatment Resistant Major Depressive Disorder
Interventions:   Procedure: Bilateral surgical implantation of DBS system to Habeluna;   Other: Follow-up Period
Sponsor:   Ruijin Hospital
Recruiting


Eealy Improvement Predicts Antidepressants Response in Adults With Major Depression Disorder


Condition:   Major Depressive Disorder
Intervention:   Drug: antidepressant
Sponsor:   Huashan Hospital
Recruiting


A Study to Evaluate the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Major Depressive Disorder


Condition:   Major Depressive Disorder
Interventions:   Drug: TS-121 10 mg;   Drug: TS-121 50 mg;   Drug: Placebo
Sponsor:   Taisho Pharmaceutical R&D Inc.
Recruiting


AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression


Condition:   Major Depressive Disorder
Interventions:   Drug: AV-101;   Drug: Placebo
Sponsor:   VistaGen Therapeutics, Inc.
Not yet recruiting


Assessment of Hedonic and Motivational States in Major Depression ( MOODDIS)


Condition:   Major Depression
Intervention:   Behavioral: Computer-based tasks
Sponsor:   Institut National de la Santé Et de la Recherche Médicale, France
Not yet recruiting


Mineralocorticoid Receptor, NMDA Receptor and Cognitive Function in Depression


Condition:   Major Depression
Interventions:   Drug: Placebo;   Drug: Fludrocortisone;   Drug: D-Cycloserine
Sponsors:   Charite University, Berlin, Germany;   NeuroCure Clinical Research Center, Charite, Berlin
Recruiting


Open Label Ketamine Treatment for Major Depressive Disorder in Veterans


Condition:   Major Depressive Disorder
Intervention:   Drug: Ketamine
Sponsor:   VA Connecticut Healthcare System
Recruiting


Efficacy of H7-Coil DTMS Compared to H1-Coil DTMS in Subjects With Major Depression Disorder (MDD)


Condition:   Major Depressive Disorder (MDD)
Interventions:   Device: H7-Coil;   Device: H1-Coil
Sponsor:   Brainsway
Recruiting


A Study to Evaluate SAGE-217 in Subjects With Moderate to Severe Major Depressive Disorder


Condition:   Major Depression
Interventions:   Drug: SAGE-217;   Drug: Placebo
Sponsor:   Sage Therapeutics
Completed


Selenium as Augmentation Treatment for Sertraline Resistant Major Depression


Condition:   Major Depression
Interventions:   Dietary Supplement: selenium supplementation;   Dietary Supplement: placebo
Sponsor:   University of Sao Paulo General Hospital
Recruiting


Impact of tDCS on Emotional Processing in Major Depression


Condition:   Major Depressive Disorder
Intervention:   Device: transcranial direct current stimulation
Sponsor:   Hôpital le Vinatier
Recruiting


Psychotherapy Plus: Combining Cognitive Behavioral Therapy With tDCS


Condition:   Major Depression
Interventions:   Behavioral: cognitive behavioral therapy;   Device: tDCS;   Device: sham-tDCS
Sponsors:   Charite University, Berlin, Germany;   University of München;   University Hospital Tuebingen;   University of Freiburg
Recruiting


Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder


Condition:   Major Depression
Interventions:   Drug: AV 101 (4-Chlorokynurenine);   Other: Placebo
Sponsor:   National Institute of Mental Health (NIMH)
Recruiting


Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment


Condition:   Major Depression Disorder
Interventions:   Drug: Adjunct brexpiprazole;   Drug: ADT
Sponsor:   H. Lundbeck A/S
Completed


Supplemental Transcranial Magnetic Stimulation (TMS) vs. Standard Medication Monotherapy for Treating Major Depression: An Exploratory Field Study


Condition:   1. Major Depressive Disorder
Interventions:   Device: Supplemental TMS;   Drug: Standard Medication Monotherapy
Sponsors:   Sheppard Pratt Health System;   Central Michigan University
Withdrawn


Brain Inflammation in Major Depressive Disorder Background


Condition:   Major Depression
Intervention:  
Sponsor:   National Institute of Mental Health (NIMH)
Completed


Comparison of Venlafaxine and Fluoxetine in the Treatment of Postmenopausal Women With Major Depression


Condition:   Major Depression
Interventions:   Drug: venlafaxine;   Drug: fluoxetine
Sponsor:   Capital Medical University
Completed


Brief Multifamily Psychoeducation for Families of Patients With Chronic Major Depression


Condition:   Major Depressive Disorder
Intervention:   Behavioral: Family psychoeducation
Sponsor:   Nagoya City University
Completed


Feasibility Study to Test Clinical Efficacy of Low Energy AC Magnetic Field to Treat Major Depression


Condition:   Major Depressive Disorder (MDD)
Interventions:   Device: NeoSync EEG Synchronization Therapy;   Device: Sham NeoSync EEG Synchronization Therapy
Sponsor:   NeoSync, Inc.
Completed


Potential Use Of Brain Network Activation Analysis to Diagnose Major Depression


Condition:   Major Depressive Disorder
Intervention:  
Sponsors:   Massachusetts General Hospital;   ElMindA Ltd
Terminated


Cysteamine Therapy for Major Depressive Disorder


Condition:   Major Depressive Disorder
Intervention:   Drug: cysteamine bitartrate
Sponsor:   Icahn School of Medicine at Mount Sinai
Terminated


Major Depressive Disorder Study In Adults


Condition:   Major Depressive Disorder
Intervention:   Drug: paroxetine CR
Sponsor:   GlaxoSmithKline
Completed

Refine Your Search Advanced Search